obesity – Page 2

Adult Overweight and Obesity Management: Key Updates from the 2025 VA/DoD Clinical Practice Guideline

By MedXY 08/27/2026

A clear, clinician-focused summary of the 2025 VA/DoD guideline update: new screening thresholds, streamlined treatment pathways, integration of pharmacotherapy (including GLP‑1 receptor agonists), endoscopic and surgical options, and veteran-centered care.

news Oncology Respiratory

Exercise Reverses Obesity-Driven Immune Dysfunction in Lung Cancer: New Insights for Therapy and Prevention

By MedXY 08/25/2026

Physical activity counteracts adiposity-induced immune suppression in lung cancer and non-tumor lungs, restoring antitumor immunity and slowing tumor progression, with implications for lung cancer interception.

news OB/GYN & Women’s Health

Tailoring Misoprostol Dosing for Labor Induction: The Influence of BMI and Administration Route

By MedXY 08/25/2026

Obesity increases the number of misoprostol doses needed for active labor during induction, with buccal dosing requiring more doses than vaginal, highlighting implications for individualized labor management.

Diabetes & Endocrinology news

Mazdutide: A Novel Dual Agonist Demonstrates Significant Weight Loss in Adults with Obesity or Overweight

By MedXY 08/22/2026

Mazdutide, a once-weekly glucagon and GLP-1 receptor dual agonist, delivers clinically meaningful weight reduction in adults with obesity or overweight, with higher doses yielding superior outcomes and manageable safety profiles.

Cardiology Diabetes & Endocrinology news

Semaglutide’s Impact on Inflammation and Cardiovascular Risk in Overweight Patients: Insights from the SELECT Trial

By MedXY 08/21/2026

In the SELECT trial, semaglutide significantly lowered hsCRP levels and major cardiovascular events in patients with established atherosclerotic cardiovascular disease and overweight or obesity, suggesting inflammation reduction as a possible mechanism behind cardiovascular benefits.

Diabetes & Endocrinology Gastroenterology news

Longitudinal Weight Changes in MASLD: Impact on Liver Outcomes and Disease Progression

By MedXY 08/19/2026

This study reveals that weight gain exceeding 5% in MASLD patients increases liver-related event risks and liver stiffness, whereas weight loss improves liver stiffness and may reduce adverse outcomes, especially with obesity reversal.

Clinical Updates news Pediatrics Psychiatry

Smartphone Acquisition at Age 13 and Its Impact on Adolescent Depression, Obesity, and Sleep: A Cohort Evidence Synthesis

By MedXY 08/16/2026

This review synthesizes evidence linking smartphone acquisition and use at age 13 to depression, obesity, and sleep insufficiency at age 14, highlighting that use intensity rather than mere acquisition mediates health risks, with behavioral strategies mitigating adverse outcomes.

Diabetes & Endocrinology news OB/GYN & Women’s Health

Impact of Semaglutide Exposure on Gestational Weight Gain and Pregnancy Outcomes in Overweight and Obese Women

By MedXY 08/14/2026

This study investigates how semaglutide exposure before and during pregnancy affects gestational weight gain and key pregnancy outcomes in women with overweight or obesity, highlighting increased risks that may stem from treatment discontinuation rather than intrauterine exposure.

General Surgery news OB/GYN & Women's Health

Metabolic and Bariatric Surgery in the Care of Endometrial Intraepithelial Neoplasia and Endometrial Cancer: Key Guidance from the SGO–SAGES Joint Statement

By MedXY 08/12/2026

A clear, evidence-based summary of the 2026 SGO–SAGES clinical practice statement recommending integration of metabolic and bariatric surgery into multidisciplinary care for women with EIN and endometrial cancer.

Clinical Updates Diabetes & Endocrinology news

Efficacy and Safety of Once-Weekly Semaglutide 2.4 mg in Chinese Adults with Overweight or Obesity: Insights from the STEP 12 Trial and Regional Evidence

By MedXY 08/11/2026

This review synthesizes evidence from the STEP 12 trial and related studies demonstrating that once-weekly semaglutide 2.4 mg significantly reduces bodyweight and improves cardiometabolic outcomes in Chinese adults with overweight or obesity, with a consistent safety profile.

Internal Medicine news Public Health

ACP 2026 Position Paper: A Policy Roadmap to Make Obesity Prevention and Treatment Affordable, Accessible, and Stigma-Free

By MedXY 08/07/2026

The American College of Physicians' 2026 position paper calls for comprehensive payer coverage, healthy food access, bias reduction, and research to tackle adult obesity through multisector public policy.

news OB/GYN & Women’s Health Oncology

Preoperative Weight Loss in Obese Women With Atypical Hyperplasia or Low-Grade Endometrial Cancer: Feasibility and Outcomes

By MedXY 08/06/2026

A medically supervised preoperative weight loss program is feasible and leads to significant short-term weight reductions in women with obesity and atypical hyperplasia or low-grade endometrial carcinoma. Further research is necessary to confirm clinical benefits.

Diabetes & Endocrinology Gastroenterology news

EndoBarrier Duodenal-Jejunal Bypass Liner: A Novel Endoscopic Adjunct for Improved Glycemic Control and Weight Loss in Type 2 Diabetes with Obesity

By MedXY 07/15/2026

The ENDO trial demonstrates that the EndoBarrier duodenal-jejunal bypass liner significantly improves glycemic control and induces meaningful weight loss in patients with poorly controlled type 2 diabetes and obesity, with an acceptable safety profile.

Diabetes & Endocrinology Internal Medicine news

Next-Generation Pharmacotherapies in Obesity: Transforming Care with Precision and Multisystem Benefits

By MedXY 07/14/2026

Emerging obesity pharmacotherapies targeting entero-pancreatic hormones deliver substantial weight loss and improve multiple obesity-related complications, heralding a treat-to-target paradigm in obesity management with personalized, complication-centric care.

news Otorhinolaryngology Pediatrics

Clinical and Polysomnographic Characteristics Distinguishing Extreme from Very Severe Pediatric Obstructive Sleep Apnea

By MedXY 07/13/2026

This study delineates phenotypic and polysomnographic differences in children with extreme versus very severe OSA, highlighting the critical role of obesity and oxygenation metrics in identifying extreme cases.

Diabetes & Endocrinology Internal Medicine news

Harnessing Real-World Evidence to Optimize GLP-1-Based Therapies: Insights from a NIDDK Workshop

By MedXY 07/07/2026

A NIDDK workshop highlighted the crucial role of real-world evidence in addressing gaps about GLP-1 receptor agonists’ safety, effectiveness, adherence, and economic impact to improve clinical and regulatory decision-making.

Diabetes & Endocrinology Gastroenterology news

Development and Validation of a Noninvasive Score for At-Risk Metabolic Dysfunction-Associated Steatohepatitis in Individuals with Obesity Undergoing Bariatric Surgery

By MedXY 07/05/2026

Researchers developed and validated the FMO score, a noninvasive, cost-effective tool to identify at-risk metabolic dysfunction-associated steatohepatitis (MASH) in obese patients, showing strong predictive performance across multiple international cohorts.

Diabetes & Endocrinology news Public Health

Baseline and Longitudinal Joint Associations of Alcohol Consumption and Obesity with Diabetes Risk: Evaluating Multiplicative and Additive Interactions

By MedXY 07/04/2026

This study examines how obesity and alcohol consumption jointly impact diabetes risk over time in an Asian cohort, highlighting differences in interaction measures and implications for diabetes prevention.

Clinical Updates Internal Medicine news Public Health

Whole-Population Trends in Obesity and Inequality in England, 2019-2025: Insights from a Cohort of 54 Million Adults

By MedXY 06/27/2026

Analyzing 54 million adults in England reveals rising obesity rates from 2019-2025, disproportionately affecting socioeconomically deprived, ethnic minority, and younger adult groups, with widening inequalities intensified during the COVID-19 pandemic.

Diabetes & Endocrinology news

Comparative 1-Year Outcomes of Semaglutide, Tirzepatide, and Sleeve Gastrectomy in Obese Adults with Type 2 Diabetes: Insights from Real-World Data

By MedXY 06/20/2026

A retrospective cohort study evaluating 1-year weight loss, glycaemic control, and safety outcomes among adults with obesity and type 2 diabetes treated with semaglutide, tirzepatide, or sleeve gastrectomy, highlighting higher efficacy with surgery but varying safety profiles.